Advertisement

Advertisement

ACTU Stock Latest News

Buy Rating Reaffirmed on Elraglusib Momentum and External Validation; $15 ACTU Price Target Maintained

RatingsBuy Rating Reaffirmed on Elraglusib Momentum and External Validation; $15 ACTU Price Target Maintained

Actuate Therapeutics Stockholders Elect Directors, Ratify Auditor

PremiumCompany Announcements

Actuate Therapeutics Stockholders Elect Directors, Ratify Auditor

1M ago

Actuate Therapeutics price target lowered to $5 from $6 at Lucid Capital

PremiumThe Fly

Actuate Therapeutics price target lowered to $5 from $6 at Lucid Capital

1M ago

Actuate Wins FDA Clearance for Oral Elraglusib Trial

PremiumCompany Announcements

Actuate Wins FDA Clearance for Oral Elraglusib Trial

1M ago

Actuate Therapeutics receives FDA clearance for oral elraglusib study

PremiumThe Fly

Actuate Therapeutics receives FDA clearance for oral elraglusib study

1M ago

Actuate Therapeutics Adds Oncology Expert to Board Leadership

PremiumCompany AnnouncementsActuate Therapeutics Adds Oncology Expert to Board Leadership

2M ago

Actuate Therapeutics management to meet with B. Riley

The Fly

Actuate Therapeutics management to meet with B. Riley

2M ago

Actuate Therapeutics price target lowered to $15 from $20 at H.C. Wainwright

The Fly

Actuate Therapeutics price target lowered to $15 from $20 at H.C. Wainwright

2M ago

Actuate launches research initiative to combine elraglusib, RAS inhibitors

PremiumThe Fly

Actuate launches research initiative to combine elraglusib, RAS inhibitors

3M ago

Actuate Therapeutics announces plans to expand clinical pipeline

PremiumThe Fly

Actuate Therapeutics announces plans to expand clinical pipeline

5M ago

Actuate Therapeutics reports positive Phase 2 pancreatic cancer data

PremiumCompany Announcements

Actuate Therapeutics reports positive Phase 2 pancreatic cancer data

5M ago

Actuate Therapeutics says Phase 2 study met primary endpoints

PremiumThe Fly

Actuate Therapeutics says Phase 2 study met primary endpoints

5M ago

Actuate announces results from Phase 1 portion of study of elraglusib

PremiumThe FlyActuate announces results from Phase 1 portion of study of elraglusib

6M ago

Actuate Therapeutics announces publication of Phase II data for elraglusib

The Fly

Actuate Therapeutics announces publication of Phase II data for elraglusib

6M ago

Actuate Therapeutics Signs $100M Sales Agreement

Company Announcements

Actuate Therapeutics Signs $100M Sales Agreement

7M ago

Actuate Therapeutics: Strategic Advancements and Financial Outlook Drive Buy Rating

PremiumRatings

Actuate Therapeutics: Strategic Advancements and Financial Outlook Drive Buy Rating

7M ago

Actuate Therapeutics Receives Buy Rating Amid Strategic Advancements and Financial Strengthening

PremiumRatings

Actuate Therapeutics Receives Buy Rating Amid Strategic Advancements and Financial Strengthening

9M ago

Actuate announces corporate update on regulatory path for elraglusib

PremiumThe Fly

Actuate announces corporate update on regulatory path for elraglusib

9M ago

Actuate Therapeutics Announces Public Offering of Shares

PremiumCompany Announcements

Actuate Therapeutics Announces Public Offering of Shares

9M ago

Actuate prices 2.14M shares at $7.00 in underwritten public offering

PremiumThe FlyActuate prices 2.14M shares at $7.00 in underwritten public offering

9M ago

Actuate Therapeutics 2.142M share Secondary priced at $7.00

The Fly

Actuate Therapeutics 2.142M share Secondary priced at $7.00

9M ago

Actuate Therapeutics announces common stock offering, no amount given

The Fly

Actuate Therapeutics announces common stock offering, no amount given

10M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >